Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Mai 2024 17:05 ET | Quelle: Affimed N.V.

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led...
24. April 2024 04:05 ET | Quelle: Affimed N.V.

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been...
05. Oktober 2022 08:05 ET | Quelle: Affimed N.V.

Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presentedIn a second poster presentation, initial phase 1 dose escalation...